A Phase Ib, Multicenter, Open-label Study of HCD122 Administered Intravenously in Combination With Bendamustine in Patients With CD40+ Follicular Lymphoma Who Are Refractory to Rituximab.
Phase of Trial: Phase I
Latest Information Update: 27 Nov 2012
At a glance
- Drugs Bendamustine; Lucatumumab
- Indications Follicular lymphoma
- Focus Adverse reactions
- Acronyms LIFT
- 27 Nov 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 30 Jul 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 01 May 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.